HAEM5:Kikuchi-Fujimoto disease: Difference between revisions

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[checked revision][checked revision]
Line 114: Line 114:
NA
NA
==Genes and Main Pathways Involved==
==Genes and Main Pathways Involved==
<big>Kikuchi-Fujimoto disease does '''not have characteristic or recurrent genetic alterations'''.</big>
<big>Kikuchi-Fujimoto disease (KFD) does '''not have characteristic or recurrent genetic alterations'''.</big>


<big>However, in a study using exome and transcriptome sequencing of lymph node tissue samples from KFD patients, fourteen '''single nucleotide polymorphisms''' were identified as candidate markers for the disease and found hundreds of genes with altered expression involving immune system, chromatin remodeling, transcription pathways.</big>  
<big>However, a study using exome and transcriptome sequencing of lymph node tissue samples from KFD patients found fourteen '''single nucleotide polymorphisms''' as possible candidate markers for the disease and hundreds of genes with altered expression involving immune system, chromatin remodeling, transcription pathways.</big><ref>{{Cite journal|last=Anuntakarun|first=Songtham|last2=Larbcharoensub|first2=Noppadol|last3=Payungporn|first3=Sunchai|last4=Reamtong|first4=Onrapak|date=2021-06|title=Identification of genes associated with Kikuchi-Fujimoto disease using RNA and exome sequencing|url=https://pubmed.ncbi.nlm.nih.gov/33819568|journal=Molecular and Cellular Probes|volume=57|pages=101728|doi=10.1016/j.mcp.2021.101728|issn=1096-1194|pmid=33819568}}</ref>  
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 129: Line 129:


==Familial Forms==
==Familial Forms==
NA
<big>Some reports describe '''HLA class II associations''' (e.g., HLA-DPA1 and HLA-DPB1 polymorphisms)</big><ref>{{Cite journal|last=Tanaka|first=T.|last2=Ohmori|first2=M.|last3=Yasunaga|first3=S.|last4=Ohshima|first4=K.|last5=Kikuchi|first5=M.|last6=Sasazuki|first6=T.|date=1999-09|title=DNA typing of HLA class II genes (HLA‐DR, ‐DQ and ‐DP) in Japanese patients with histiocytic necrotizing lymphadenitis (Kikuchi’s disease)|url=https://onlinelibrary.wiley.com/doi/10.1034/j.1399-0039.1999.540305.x|journal=Tissue Antigens|language=en|volume=54|issue=3|pages=246–253|doi=10.1034/j.1399-0039.1999.540305.x|issn=0001-2815}}</ref> <big>in certain populations</big><big>, suggesting a genetic susceptibility</big> <big>and rare reports in siblings suggest familial susceptibility</big><big>.</big><ref>{{Cite journal|last=Isoda|first=Atsushi|last2=Tahara|first2=Kenichi|last3=Ide|first3=Munenori|date=2023-12|title=Kikuchi-Fujimoto Disease in Human Leukocyte Antigen Partially Matched Siblings: A Case Study of Familial Susceptibility|url=https://pubmed.ncbi.nlm.nih.gov/38264372|journal=Cureus|volume=15|issue=12|pages=e51010|doi=10.7759/cureus.51010|issn=2168-8184|pmc=10803893|pmid=38264372}}</ref>


==Additional Information==
==Additional Information==
<big>Most published studies indicate a '''reactive, immune-mediated process''' rather than a neoplastic one. Some reports describe '''HLA class II associations''' (e.g., HLA-DPA1 and HLA-DPB1 polymorphisms)</big><ref>{{Cite journal|last=Tanaka|first=T.|last2=Ohmori|first2=M.|last3=Yasunaga|first3=S.|last4=Ohshima|first4=K.|last5=Kikuchi|first5=M.|last6=Sasazuki|first6=T.|date=1999-09|title=DNA typing of HLA class II genes (HLA‐DR, ‐DQ and ‐DP) in Japanese patients with histiocytic necrotizing lymphadenitis (Kikuchi’s disease)|url=https://onlinelibrary.wiley.com/doi/10.1034/j.1399-0039.1999.540305.x|journal=Tissue Antigens|language=en|volume=54|issue=3|pages=246–253|doi=10.1034/j.1399-0039.1999.540305.x|issn=0001-2815}}</ref> <big>in certain populations</big><big>, suggesting a genetic susceptibility.</big><ref>{{Cite journal|last=Isoda|first=Atsushi|last2=Tahara|first2=Kenichi|last3=Ide|first3=Munenori|date=2023-12|title=Kikuchi-Fujimoto Disease in Human Leukocyte Antigen Partially Matched Siblings: A Case Study of Familial Susceptibility|url=https://pubmed.ncbi.nlm.nih.gov/38264372|journal=Cureus|volume=15|issue=12|pages=e51010|doi=10.7759/cureus.51010|issn=2168-8184|pmc=10803893|pmid=38264372}}</ref>
<big>Most published studies indicate a '''reactive, immune-mediated process''' rather than a neoplastic one.</big><ref>{{Cite journal|last=Li|first=Elizabeth Y.|last2=Xu|first2=Jason|last3=Nelson|first3=Nya D.|last4=Teachey|first4=David T.|last5=Tan|first5=Kai|last6=Romberg|first6=Neil|last7=Behrens|first7=Ed|last8=Pillai|first8=Vinodh|date=2022-04|title=Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response|url=https://pubmed.ncbi.nlm.nih.gov/34952944|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=35|issue=4|pages=462–469|doi=10.1038/s41379-021-00992-7|issn=1530-0285|pmid=34952944}}</ref>  
 
Exomes and transcriptomes of lymph node tissue samples from KFD patients were analyzed by DNA sequencing. Fourteen single nucleotide polymorphisms (SNPs) were identified as candidate KFD markers and found hundreds of genes with altered expression (238 up, 1,519 down) involving immune system, chromatin remodeling, transcription pathways.


==Links==
==Links==

Revision as of 20:00, 6 November 2025

Haematolymphoid Tumours (WHO Classification, 5th ed.)

Primary Author(s)*

Sumire Kitahara, MD

WHO Classification of Disease

Structure Disease
Book Haematolymphoid Tumours (5th ed.)
Category T-cell and NK-cell lymphoid proliferations and lymphomas
Family Tumour-like lesions with T-cell predominance
Type N/A
Subtype(s) Kikuchi-Fujimoto disease

Related Terminology

Acceptable Histiocytic necrotizing lymphadenitis; Kikuchi disease; Kikuchi lymphadenitis
Not Recommended N/A

Gene Rearrangements

Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.

Driver Gene Fusion(s) and Common Partner Genes Molecular Pathogenesis Typical Chromosomal Alteration(s) Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease) Diagnostic, Prognostic, and Therapeutic Significance - D, P, T Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes
NA

Individual Region Genomic Gain/Loss/LOH

Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.

Chr # Gain, Loss, Amp, LOH Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size] Relevant Gene(s) Diagnostic, Prognostic, and Therapeutic Significance - D, P, T Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes
NA

Characteristic Chromosomal or Other Global Mutational Patterns

Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.

Chromosomal Pattern Molecular Pathogenesis Prevalence -

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

Diagnostic, Prognostic, and Therapeutic Significance - D, P, T Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes
NA

Gene Mutations (SNV/INDEL)

Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.

Gene Genetic Alteration Tumor Suppressor Gene, Oncogene, Other Prevalence -

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

Diagnostic, Prognostic, and Therapeutic Significance - D, P, T   Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes
NA

Epigenomic Alterations

NA

Genes and Main Pathways Involved

Kikuchi-Fujimoto disease (KFD) does not have characteristic or recurrent genetic alterations.

However, a study using exome and transcriptome sequencing of lymph node tissue samples from KFD patients found fourteen single nucleotide polymorphisms as possible candidate markers for the disease and hundreds of genes with altered expression involving immune system, chromatin remodeling, transcription pathways.[1]

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
NA

Genetic Diagnostic Testing Methods

Genetic testing is non-contributory to rule-in a diagnosis of Kikuchi-Fujimoto disease. If the morphology and immunophenotype raise concern for lymphoma, particularly of T-lineage, genetic testing (e.g. T-cell receptor gene rearrangement, cytogenetic and/or NGS studies) may play a role.

Familial Forms

Some reports describe HLA class II associations (e.g., HLA-DPA1 and HLA-DPB1 polymorphisms)[2] in certain populations, suggesting a genetic susceptibility and rare reports in siblings suggest familial susceptibility.[3]

Additional Information

Most published studies indicate a reactive, immune-mediated process rather than a neoplastic one.[4]

Links

NA

References

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the Associate Editor or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.


*Citation of this Page: “Kikuchi-Fujimoto disease”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 11/6/2025, https://ccga.io/index.php/HAEM5:Kikuchi-Fujimoto_disease.

  1. Anuntakarun, Songtham; et al. (2021-06). "Identification of genes associated with Kikuchi-Fujimoto disease using RNA and exome sequencing". Molecular and Cellular Probes. 57: 101728. doi:10.1016/j.mcp.2021.101728. ISSN 1096-1194. PMID 33819568 Check |pmid= value (help). Check date values in: |date= (help)
  2. Tanaka, T.; et al. (1999-09). "DNA typing of HLA class II genes (HLA‐DR, ‐DQ and ‐DP) in Japanese patients with histiocytic necrotizing lymphadenitis (Kikuchi's disease)". Tissue Antigens. 54 (3): 246–253. doi:10.1034/j.1399-0039.1999.540305.x. ISSN 0001-2815. Check date values in: |date= (help)
  3. Isoda, Atsushi; et al. (2023-12). "Kikuchi-Fujimoto Disease in Human Leukocyte Antigen Partially Matched Siblings: A Case Study of Familial Susceptibility". Cureus. 15 (12): e51010. doi:10.7759/cureus.51010. ISSN 2168-8184. PMC 10803893 Check |pmc= value (help). PMID 38264372 Check |pmid= value (help). Check date values in: |date= (help)
  4. Li, Elizabeth Y.; et al. (2022-04). "Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 35 (4): 462–469. doi:10.1038/s41379-021-00992-7. ISSN 1530-0285. PMID 34952944 Check |pmid= value (help). Check date values in: |date= (help)